Replimune Group (REPL) Competitors $7.60 +0.57 (+8.11%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.71 +0.11 (+1.50%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. BGM, ORIC, IMNM, AKBA, ZYME, NRIX, PROK, TRVI, LENZ, and MLYSShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include BGM Group (BGM), Oric Pharmaceuticals (ORIC), Immunome (IMNM), Akebia Therapeutics (AKBA), Zymeworks (ZYME), Nurix Therapeutics (NRIX), ProKidney (PROK), Trevi Therapeutics (TRVI), LENZ Therapeutics (LENZ), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors BGM Group Oric Pharmaceuticals Immunome Akebia Therapeutics Zymeworks Nurix Therapeutics ProKidney Trevi Therapeutics LENZ Therapeutics Mineralys Therapeutics BGM Group (NASDAQ:BGM) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment. Do institutionals and insiders hold more shares of BGM or REPL? 92.5% of Replimune Group shares are owned by institutional investors. 58.7% of BGM Group shares are owned by insiders. Comparatively, 8.8% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate BGM or REPL? Replimune Group has a consensus target price of $7.67, suggesting a potential upside of 0.88%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than BGM Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Replimune Group 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.33 Which has more risk and volatility, BGM or REPL? BGM Group has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Which has higher valuation & earnings, BGM or REPL? BGM Group has higher revenue and earnings than Replimune Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBGM Group$25.10M33.31-$1.44MN/AN/AReplimune GroupN/AN/A-$247.30M-$3.07-2.48 Does the media prefer BGM or REPL? In the previous week, Replimune Group had 44 more articles in the media than BGM Group. MarketBeat recorded 44 mentions for Replimune Group and 0 mentions for BGM Group. Replimune Group's average media sentiment score of 0.09 beat BGM Group's score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media. Company Overall Sentiment BGM Group Neutral Replimune Group Neutral Is BGM or REPL more profitable? BGM Group's return on equity of 0.00% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets BGM GroupN/A N/A N/A Replimune Group N/A -57.98%-45.21% SummaryReplimune Group beats BGM Group on 7 of the 13 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$546.98M$2.99B$5.48B$9.53BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-2.4817.7428.8623.83Price / SalesN/A178.71371.4466.13Price / CashN/A41.9535.4557.96Price / Book1.418.508.265.54Net Income-$247.30M-$55.06M$3.25B$259.28M7 Day Performance141.27%-3.99%-3.73%-4.67%1 Month Performance-20.42%9.58%4.28%4.38%1 Year Performance-24.75%6.70%25.85%17.90% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group3.8836 of 5 stars$7.60+8.1%$7.67+0.9%-25.6%$546.98MN/A-2.48210Trending NewsAnalyst UpgradeOptions VolumeGap DownBGMBGM GroupN/A$10.04-3.9%N/AN/A$976.09M$25.10M0.00298High Trading VolumeORICOric Pharmaceuticals4.5534 of 5 stars$11.18-2.3%$18.57+66.1%-4.6%$952.76MN/A-5.9880News CoveragePositive NewsIMNMImmunome1.9944 of 5 stars$10.84-0.3%$23.33+115.3%-29.7%$943.19M$9.04M-3.4140News CoveragePositive NewsGap DownAKBAAkebia Therapeutics3.7069 of 5 stars$3.59+0.8%$6.75+88.0%+188.4%$942.86M$184.91M-17.09430News CoverageUpcoming EarningsZYMEZymeworks2.8802 of 5 stars$13.46+1.0%$21.00+56.0%+24.3%$937.93M$93.38M-8.97460Upcoming EarningsNRIXNurix Therapeutics2.6688 of 5 stars$11.93+3.6%$29.31+145.7%-48.6%$912.05M$54.55M-4.57300News CoverageAnalyst ForecastPROKProKidney3.2891 of 5 stars$3.08-6.4%$6.25+102.9%+29.4%$901.52M$80K-5.133Upcoming EarningsGap DownTRVITrevi Therapeutics2.7757 of 5 stars$7.64-2.9%$20.88+173.2%+136.5%$896.10MN/A-16.9820News CoverageUpcoming EarningsShort Interest ↑LENZLENZ Therapeutics1.6834 of 5 stars$31.51-0.3%$48.60+54.2%+21.7%$887.01MN/A-17.80110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMLYSMineralys Therapeutics2.5512 of 5 stars$13.60-5.0%$32.25+137.1%+13.4%$886.38MN/A-3.6528News CoverageInsider Trade Related Companies and Tools Related Companies BGM Group Alternatives Oric Pharmaceuticals Alternatives Immunome Alternatives Akebia Therapeutics Alternatives Zymeworks Alternatives Nurix Therapeutics Alternatives ProKidney Alternatives Trevi Therapeutics Alternatives LENZ Therapeutics Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
